402 related articles for article (PubMed ID: 21769763)
21. Influence of (11)C-choline PET/CT on the treatment planning for salvage radiation therapy in patients with biochemical recurrence of prostate cancer.
Souvatzoglou M; Krause BJ; Pürschel A; Thamm R; Schuster T; Buck AK; Zimmermann F; Molls M; Schwaiger M; Geinitz H
Radiother Oncol; 2011 May; 99(2):193-200. PubMed ID: 21620494
[TBL] [Abstract][Full Text] [Related]
22. Diagnostic performance of
Samper Ots P; Luis Cardo A; Vallejo Ocaña C; Cabeza Rodríguez MA; Glaria Enríquez LA; Couselo Paniagua ML; Olivera Vegas J
Clin Transl Oncol; 2019 Jun; 21(6):766-773. PubMed ID: 30448957
[TBL] [Abstract][Full Text] [Related]
23. Diagnostic imaging work-up for disease relapse after radical treatment for prostate cancer: how to differentiate local from systemic disease? The urologist point of view.
Schiavina R; Brunocilla E; Borghesi M; Vagnoni V; Castellucci P; Nanni C; Ceci F; Gacci M; Martorana G; Fanti S
Rev Esp Med Nucl Imagen Mol; 2013; 32(5):310-3. PubMed ID: 23933383
[TBL] [Abstract][Full Text] [Related]
24. A literature review of 18F-fluoride PET/CT and 18F-choline or 11C-choline PET/CT for detection of bone metastases in patients with prostate cancer.
Wondergem M; van der Zant FM; van der Ploeg T; Knol RJ
Nucl Med Commun; 2013 Oct; 34(10):935-45. PubMed ID: 23903557
[TBL] [Abstract][Full Text] [Related]
25. [11C]Choline-PET/CT for outcome prediction of salvage radiotherapy of local relapsing prostate carcinoma.
Reske SN; Moritz S; Kull T
Q J Nucl Med Mol Imaging; 2012 Oct; 56(5):430-9. PubMed ID: 23069922
[TBL] [Abstract][Full Text] [Related]
26. Choline PET or PET/CT and biochemical relapse of prostate cancer: a systematic review and meta-analysis.
Evangelista L; Zattoni F; Guttilla A; Saladini G; Zattoni F; Colletti PM; Rubello D
Clin Nucl Med; 2013 May; 38(5):305-14. PubMed ID: 23486334
[TBL] [Abstract][Full Text] [Related]
27. Meta-analysis of (11)C-choline and (18)F-choline PET/CT for management of patients with prostate cancer.
von Eyben FE; Kairemo K
Nucl Med Commun; 2014 Mar; 35(3):221-30. PubMed ID: 24240194
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of extraprostatic disease in the staging of prostate cancer by F-18 choline PET/CT: can PSA and PSA density help in patient selection?
Calabria F; Chiaravalloti A; Tavolozza M; Ragano-Caracciolo C; Schillaci O
Nucl Med Commun; 2013 Aug; 34(8):733-40. PubMed ID: 23680652
[TBL] [Abstract][Full Text] [Related]
29. ¹⁸F-NaF PET/CT and ¹¹C-Choline PET/CT for the initial detection of metastatic disease in prostate cancer: overview and potential utilization.
Koo PJ; David Crawford E
Oncology (Williston Park); 2014 Dec; 28(12):1057-62, 1064-5. PubMed ID: 25738199
[TBL] [Abstract][Full Text] [Related]
30. Role of 11C-choline PET/CT in the restaging of prostate cancer patients showing a single lesion on bone scintigraphy.
Fuccio C; Castellucci P; Schiavina R; Santi I; Allegri V; Pettinato V; Boschi S; Martorana G; Al-Nahhas A; Rubello D; Fanti S
Ann Nucl Med; 2010 Jul; 24(6):485-92. PubMed ID: 20544323
[TBL] [Abstract][Full Text] [Related]
31. Comparison of (11)C-choline PET/CT and enhanced CT in the evaluation of patients with pulmonary abnormalities and locoregional lymph node involvement in lung cancer.
Peng Z; Liu Q; Li M; Han M; Yao S; Liu Q
Clin Lung Cancer; 2012 Jul; 13(4):312-20. PubMed ID: 22182444
[TBL] [Abstract][Full Text] [Related]
32. Role of choline PET/CT in guiding target volume delineation for irradiation of prostate cancer.
Schwarzenböck SM; Kurth J; Gocke Ch; Kuhnt T; Hildebrandt G; Krause BJ
Eur J Nucl Med Mol Imaging; 2013 Jul; 40 Suppl 1():S28-35. PubMed ID: 23576101
[TBL] [Abstract][Full Text] [Related]
33. Pattern of occult nodal relapse diagnosed with (18)F-fluoro-choline PET/CT in prostate cancer patients with biochemical failure after prostate-only radiotherapy.
Lépinoy A; Cochet A; Cueff A; Cormier L; Martin E; Maingon P; Bosset JF; Brunotte F; Créhange G
Radiother Oncol; 2014 Apr; 111(1):120-5. PubMed ID: 24780635
[TBL] [Abstract][Full Text] [Related]
34. Utility of choline positron emission tomography/computed tomography for lymph node involvement identification in intermediate- to high-risk prostate cancer: a systematic literature review and meta-analysis.
Evangelista L; Guttilla A; Zattoni F; Muzzio PC; Zattoni F
Eur Urol; 2013 Jun; 63(6):1040-8. PubMed ID: 23036576
[TBL] [Abstract][Full Text] [Related]
35. Role of 18F-choline PET/CT in biochemically relapsed prostate cancer after radical prostatectomy: correlation with trigger PSA, PSA velocity, PSA doubling time, and metastatic distribution.
Marzola MC; Chondrogiannis S; Ferretti A; Grassetto G; Rampin L; Massaro A; Castellucci P; Picchio M; Al-Nahhas A; Colletti PM; Marcolongo A; Rubello D
Clin Nucl Med; 2013 Jan; 38(1):e26-32. PubMed ID: 23242060
[TBL] [Abstract][Full Text] [Related]
36. Influence of trigger PSA and PSA kinetics on 11C-Choline PET/CT detection rate in patients with biochemical relapse after radical prostatectomy.
Castellucci P; Fuccio C; Nanni C; Santi I; Rizzello A; Lodi F; Franceschelli A; Martorana G; Manferrari F; Fanti S
J Nucl Med; 2009 Sep; 50(9):1394-400. PubMed ID: 19690023
[TBL] [Abstract][Full Text] [Related]
37. [Biochemical recurrence after curative treatment for localized prostate cancer: Performance of choline PET/CT in the assessment of local recurrence].
Poncet D; Arnoux V; Descotes JL; Rambeaud JJ; Verry C; Terrier N; Boillot B; Dubreuil J; Lanchon C; Carnicelli D; Fiard G; Long JA
Prog Urol; 2015 May; 25(6):325-30. PubMed ID: 25748788
[TBL] [Abstract][Full Text] [Related]
38. Gleason score at diagnosis predicts the rate of detection of 18F-choline PET/CT performed when biochemical evidence indicates recurrence of prostate cancer: experience with 1,000 patients.
Cimitan M; Evangelista L; Hodolič M; Mariani G; Baseric T; Bodanza V; Saladini G; Volterrani D; Cervino AR; Gregianin M; Puccini G; Guidoccio F; Fettich J; Borsatti E
J Nucl Med; 2015 Feb; 56(2):209-15. PubMed ID: 25552670
[TBL] [Abstract][Full Text] [Related]
39. Choline PET/CT for imaging prostate cancer: an update.
Kitajima K; Murphy RC; Nathan MA
Ann Nucl Med; 2013 Aug; 27(7):581-91. PubMed ID: 23632880
[TBL] [Abstract][Full Text] [Related]
40. Value of PET/CT and MR lymphography in treatment of prostate cancer patients with lymph node metastases.
Fortuin AS; Deserno WM; Meijer HJ; Jager GJ; Takahashi S; Debats OA; Reske SN; Schick C; Krause BJ; van Oort I; Witjes AJ; Hoogeveen YL; van Lin EN; Barentsz JO
Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):712-8. PubMed ID: 22417806
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
